Kumaraguru Raja

Stock Analyst at Brookline Capital

(0)
# 5007
Out of 5,298 analysts
19
Total ratings
18.18%
Success rate
-37.83%
Average return
Main Sectors:
Top Industries:
16 Stocks
Name Action Price Target Current % Upside Ratings Updated
QNCX Quince Therapeutics
Initiates Coverage On: Buy
9
1.27 608.66% 1 Dec 18, 2024
PALI Palisade Bio
Initiates Coverage On: Buy
38
0.64 5837.5% 1 Nov 20, 2024
SABS SAB Biotherapeutics
Initiates Coverage On: Buy
8
1.19 572.27% 1 Jun 7, 2024
FBRX Forte Biosciences
Initiates Coverage On: Buy
100
6.52 1433.74% 2 May 30, 2024
HEPA Hepion Pharmaceutica...
Downgrades: Hold
n/a
n/a n/a 1 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Aug 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
150
0.7 21328.57% 2 Jul 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
15
3.88 286.6% 1 Jun 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
9
n/a n/a 1 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
21
2.05 924.39% 1 Jan 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
15
n/a n/a 1 Jan 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
90
34.66 159.67% 1 Dec 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
29 31
0.58 5244.83% 2 May 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
3360
0.96 349900% 1 Sep 21, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
320
n/a n/a 1 Mar 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
120
n/a n/a 1 Mar 25, 2021